Surgical Science Sweden AB (OTCPK:SUSRF)

Q4 2025 Surgical Science Sweden AB Earnings Call Transcript

Feb 19, 2026 / 10:00 AM GMT

Release Date Price: $2.84

Transcript

Key Points

Positve

Surgical Science Sweden AB (SUSRF) reported a 15% sales growth in Q4 2025, adjusted for currency effects.
License revenues, primarily from robotics companies, reached an all-time high of 92 million SEK, marking a 21% increase.
The company introduced a new partner path distributor program aimed at improving cooperation, sales, and efficiency, contributing to increased profitability.
The ultrasound segment saw a 48% increase in sales compared to Q4 2024, with new simulation models launched, including one for diagnosing endometriosis.
Surgical Science Sweden AB (SUSRF) is developing simulation solutions for most of the 20 largest robotics companies, indicating strong market penetration and future growth potential.

Negative

Sales in Asia declined by 21%, driven by a challenging market situation in China with lower activity and demand.
The cancellation of a memorandum of understanding with Intuitive is expected to negatively impact license revenues by 60 to 90 million SEK in 2026.
Simulator sales within the industry business area were down 12% compared to Q4 2024, indicating variability in project-based revenues.
The gross margin decreased to 66% from 68% in Q4 2024, partly due to currency effects and lower margins on Intelligent Ultrasound products.
The operating result for Intelligent Ultrasound was a loss of approximately 5 million SEK for the quarter, highlighting ongoing challenges in this segment.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

SUSW.ST - Surgical Science Sweden AB
Q4 2025 Surgical Science Sweden AB Earnings Call
Feb 19, 2026 / 10:00AM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Welcome to Surgical Science Q4 Report 2025 presentation. During the Q&A session, participants can ask questions by pressing pound 5 on their telephone keypad. During the Q&A, we kindly ask participants to limit yourselves to two questions at first. If you have additional questions, please queue up again by pressing pound 5. Now I will hand over to the speakers CEO Tom Engle and CFO Anna Ahlberg. Please go ahead.

--------------------------------------------------------------------------------
Unidentified_2 [2]
--------------------------------------------------------------------------------
Welcome to this earnings call for surgical Science for the 4th quarter of 2025. My name is Tom England,

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.